TABLE 3.
Delavirdine pharmacokinetic parameters (means ± SD) following administration of delavirdine mesylate (400 mg every 8 h, with meals) to HIV-1 infected patients
| Drug(s) (no. of patients) | AUC0-8 (μM · h) | Cmax (μM) | Tmax (h) | Cmin (μM) | CLF/CLMb |
|---|---|---|---|---|---|
| Delavirdine plus ritonavir (12) | 114 ± 75 | 23 ± 16 | 2.4 ± 2.7 | 9.1 ± 7.5 | 0.29 ± 0.15 |
| Delavirdine without ritonavir (13)a | 132 ± 87 | 23 ± 13 | 1.0 ± 0.9 | 11 ± 9 | 0.36 ± 0.58 |
a
A previous study (14) with 13 patients was used as a control.
b
CLF, formation clearance; CLM, elimination clearance.